

MGC: Its Status and Future

Interactome Networks August 30, 2006

Daniela S. Gerhard, Ph.D.

Director, Office of Cancer Genomics

National Cancer Institute

Acknowledgements:




- ➤ Gary Temple
 - National Human Genome Research Institute
- ➤ Lukas Wagner, Wonhee Jang
 - National Center for Biotechnology Information
- ➤ Christa Prange Pennacchio
 - Lawrence Livermore National Laboratories,
 IMAGE
- MGC Project Team
 - 100+ individuals; for a complete list see:
 - Gerhard et al., Gen Research 14:2121, 2004

Outline



- > FL clones from cDNA libraries (Phase I)
- PCR Generation of Human & Mouse Full-CDS Clones (Phase II)
- ➤ De novo Predictions of Human Exons, Genes, & Full-CDS Sequences (Phase III)
- Results of DNA Synthesis Pilot & Follow-up for Human and Mouse (Phase IV)
- Human ORFeome Collaboration



MGC: Phase I XGC ZGC

Method:



- Unidirectional cDNA libraries made by a number of academic laboratories and contractors
- ➤ 5' reads from 5,000 20,000 clones
 - >Xenopus also has 3' reads
- ➤ 5' EST used to predict initiator methionine by 4 alternative methods
 - ➤ Match to RefSeq
 - ➤ Protein comparison
 - ➤ GenomeScan comparison
 - >HKScan starts (human and mouse only)

Current Status



mgc.nci.nih.gov

21-Aug-06	Human	Mouse	Rat	Cow
Total MGC full ORF clones	24,014	19,096	5,058	4,680
Non-redundant genes	14,172	13,332	4,773	4,130
Candidate clones for full-length sequencing	3,054	1,361	794	4,076
Goal	18,368	18,471	6250	10,000
% of goal	77.2	72.2	76.4	41.3



IMAGE Consortium Distributors

MGC Home

Clone Info

- Vectors & Method Overviews

- Candidate Clones for Genes
- MGC **ESTs**

MGC Info

- Project Summary |
- Project Teams
- NIH Institutes
- References

Other Species Collections

- Danio
- Xenopus

> American Type Culture Collection


Sequencing Info > Invitrogen, Inc

➤ Open Biosystems

> MRC Geneservice

Resource Center of the German Human Genome Project

Current Status



xgc.nci.nih.gov

Under the auspices of NIHCD (S. Klein & D.S. Gerhard) Collaboration with JGI: Erika Lindquist and P. Richardson

	21-Aug-06	laevis	tropicalis
	Total XGC full ORF clones	8,867	3,528
111 9	Non-redundant genes	8,422	2,909
	Candidate clones for full- length sequencing	661	3,807
	Goal (estimates)	9,200	9,000
7	% of goal	91.5	32.3



Analysis: 8049 FL cDNA from X. laevis

2918 FL cDNA from X. tropicalis

Results: 445 gene trios (allotetraploidization-

derived X. laevis gene pair and their

shared *X. tropicalis* ortholog)

d_N/d_s comparisons within trios show

evidence for purifying selection

d_N/d_s ratios within *X. laevis* are

significantly elevated, i.e. relaxation of

selective pressures on duplicated

gene pairs


Current Status




zgc.nci.nih.gov Under the auspices of NIDDK R. Rasooli

21-Aug-06	#
Total ZGC full ORF clones	8,771
Non-redundant genes	7,640
Candidate clones for full-length sequencing	1,173
Goal	15,000
% goal	50.9

MGC Progress as of August 4, 2006






MGC: Phase II PCR-based cloning


Pilot: 2003

Full scale: 2004

ORF Cloning by PCR Rescue



Progress of Homo sapiens clones by method



Accomplished



➤ For ~80% completed 2 attempts with a composite success rate between 50-60%

		<u># of</u>	genes targeted	obtained'
--	--	-------------	----------------	-----------

0,102	Human	6,462	3,032
-------	-------------------------	-------	-------

- Mouse 6,003 1,984


- Total 12,465 5,016

*as of August 25, 2006

Issues Encountered




- > Targets were not stable
 - > XM_# vs. NM_#
 - Duplicate selections
- Alternative splicing
 - > Effect on QC process
- ➤ Tracking for one group—3 sites
 - Cloning and EST generation
 - Picking of clones for FL
 - > FL sequencing on 3rd
- ➤ Labor intensive in all steps



MGC: Phase III Genes without (much) experimental evidence


"C List" of Human Exon Predictions (M. Brent et al., & Haussler et. al.)

(as of January 2006)



About 500 predictions, which had at least parts of the transcript already verified by PCR were submitted to BCM for cloning

Novel Single Exon Gene Identification (D. Haussler & A. Siepel, UCSC & Cornell U.)



RT-PCR of the eight single exon genes (SEGs)

RT-PCR targets:

- 1. chr19.42.008
- 2. chr2.375.17
- 3. chr20.63.017
- 4. chr2.56.006
- 5. chr5.168.006
- 6. chr21.723.9
- 7. chr18.151.3
- 8. chr17.35.001


Expected sizes

(w/ gateway tails)

- 1. 404 bp
- 2.470 bp
- 3. 614 bp
- 4.638 bp
- 5. 776 bp
- 6.812 bp
- 7. 962 bp
- 8. 1,197 bp




1 2 3 4 5 6 7 8 M




-RT control

1 2 3 4 5 6 7 8 M




+RT (N₆ priming)


1 2 3 4 5 6 7 8 M



-RT control

1 2 3 4 5 6 7 8 M





MGC: Phase IV In vitro Synthesis

DNA Synthesis Pilot



4 contractors

Each assigned a unique set of 18 targets (0.5-6kb, total of 65 kb) + same 3 ORFs >6kb:


Factor V NM_000130 cds= 6,675

APC NM_000038 cds= 8,532

Dystrophin NM_004006 cds=11,058

- pENTR223.1-Sfi or pDONR223.1
- All delivered sequence-verified clones, sequences, and sequence traces


Missing human and mouse genes as of June 2006



Completing the Human and Mouse Collection through Synthesis



- ➤ Estimated # of genes with RefSeq ID that will be verified by NCBI
 - ~2500 (almost equally divided between the 2 species)
- > Expression ready vectors
- > Exploring the option of 2 versions
 - with STOP codon
 - without STOP codon
- > Size is directly proportional to cost



ORFeome Collection & MGC

ORFeome Collaboration



Current participants


- Dana Farber-CCSB (DF-CCSB)
- Deutches Krebsforshungszentrum (DKFZ)
- Harvard Institute of Proteomics (HIP)
- IMAGE Consortium-LLNL
- Kazusa DNA Research Institute
- Mammalian Gene Collection (MGC)
- RIKEN Yokohama Institute
- Wellcome Trust-Sanger Institute (WTSI)

Human ORFeome Collaboration



Shared Goals:

- Complete collection of human full-ORF cDNA clones (for ~18,400 genes)*
- Expression-convenient format (Gateway Entry clones)
- ➤ ORFs + stop amino acids & stop amino acid (for C-fusions)
 - Current plan without STOP amino acid
- Sequence-verified clones
- Unrestricted worldwide availability



MGC: Its Status and Future

Interactome Networks August 30, 2006

Daniela S. Gerhard, Ph.D.

Director, Office of Cancer Genomics,

National Cancer Institute, NIH